Page 5 - Sofinnova Partners News Today

01.11.2023 - LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that it has entered into a definitive ...

The Inari deal comes weeks after LimFlow won FDA premarket approval for its breakthrough system to treat chronic limb-threatening ischemia.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

European Union lawmakers are being urged to avoid too much risk aversion from holding back the potential of the homegrown biotech sector.

Speaking to Fortune Andy Dunn highlighted the power of personal disclosure as a leadership strategy.

European Union lawmakers are being urged to avoid too much risk aversion from holding back the potential of the homegrown biotech sector. Beyond huge promise in healthcare, innovative, low carbon applications in areas like agriculture and food systems and energy production could help address pressing environmental and sustainability challenges.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The French biotech company reportedly closed an ‘oversubscribed’ round of equity financing that would enable the firm to ramp up the production of dairy-identical proteins.

Lyon, France-based precision fermentation startup Bon Vivant, which is using biotech techniques to reprogram yeast microorganisms to produce animal-free milk proteins with a substantially lower environmental footprint than traditional dairy, credits clarity of strategy and execution for keeping its investors enthused at a time when raising remains a challenge for many tech founders. All the investors in its April 2022 pre-seed (€4M) followed on for the oversubscribed €15M (~$15.9M...